Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Greenwich LifeSciences (GLSI)
NASDAQ:GLSI
RESEARCH TOOLSreports
Holding GLSI?
Track your performance easily
GLSI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.58 - $21.44
Previous Close$14.89
Volume35.58K
Average Volume (3M)46.23K
Market Cap
$197.17M
Enterprise Value$188.50M
Total Cash (Recent Filing)$7.22M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.32
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding13,144,653
10 Day Avg. Volume50,926
30 Day Avg. Volume46,233
Standard Deviation0.89
R-Squared0.03
Alpha0.09
Financial Highlights & Ratios
Price to Book (P/B)33.09
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-44.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-18.45
Forecast
1Y Price Target
$38.00Price Target Upside153.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Greenwich LifeSciences News
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyGLSI-100 treatment resulted in no recurrences or a 100% reduction in recurrence rate in the sub-population that the FLAMINGO-01 trial design has been based upon.
Clinical TrialsThe company is expanding the Phase 3 FLAMINGO-01 trial into Europe, including Spain, France, Germany, Italy, and Poland.
Safety ProfileNo serious adverse events related to GLSI-100 have been reported to date.
Bears Say
Capital RequirementsThe company may need to raise additional capital within the next 12 months.
Financial PerformanceNet loss totaled $2.5M in 1Q24.
Liquidity ConcernsThe company may need to raise additional capital within the next 12 months.
---
Ownership Overview
94.36% Insiders
2.19% Mutual Funds
3.39% Other Institutional Investors
0.06% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
GLSI FAQ
What was Greenwich LifeSciences’s price range in the past 12 months?
Greenwich LifeSciences lowest stock price was $7.58 and its highest was $21.44 in the past 12 months.
What is Greenwich LifeSciences’s market cap?
Currently, no data Available
When is Greenwich LifeSciences’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Greenwich LifeSciences’s earnings last quarter?
Currently, no data Available
Is Greenwich LifeSciences overvalued?
According to Wall Street analysts Greenwich LifeSciences’s price is currently Undervalued.
Does Greenwich LifeSciences pay dividends?
Greenwich LifeSciences does not currently pay dividends.
What is Greenwich LifeSciences’s EPS estimate?
Greenwich LifeSciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Greenwich LifeSciences have?
Greenwich LifeSciences has 13,144,653 shares outstanding.
What happened to Greenwich LifeSciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Greenwich LifeSciences?
Currently, no hedge funds are holding shares in GLSI
---
Greenwich LifeSciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$38.00 (153.33% Upside)
$38.00 (153.33% Upside)
Insider Transactions
Bought Shares
Worth $166.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
67.11%
12-Months-Change
Fundamentals
Return on Equity
-123.67%
Trailing 12-Months
Asset Growth
-34.00%
Trailing 12-Months
Company Description
Greenwich LifeSciences
Greenwich LifeSciences Inc is a clinical stage bio-pharmaceutical company focused on the development of an immunotherapy to prevent breast cancer recurrences in patients.
---
GLSI Stock 12 Month Forecast
Average Price Target
$38.00
▲(153.33% Upside)
Technical Analysis
Cellectar Biosciences
―
Kintara Therapeutics
―
TRACON Pharmaceuticals
―
CASI Pharmaceuticals
―
Best Analysts Covering GLSI
1 Year
1 Year Success Rate
5/9 ratings generated profit
1 Year Average Return
+2.91%
reiterated a buy rating 29 days ago
Copying Yi Chen's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +2.91% per trade.
---